Details for Patent: 7,612,102

Which drugs does patent 7,612,102 protect, and when does it expire?

Patent 7,612,102 protects CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, and CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, and is included in one NDA.

This patent has twenty-one patent family members in ten countries.

Summary for Patent: 7,612,102

Title:	Pre-mixed, ready-to-use pharmaceutical compositions
Abstract:	Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.
Inventor(s):	Michelle Renee Duncan, Supriya Gupta, David Hartley Haas, Norma V. Stephens, Camellia Zamiri
Assignee:	EKR Therapeutics Inc, Chiesi USA Inc
Application Number:	US11/788,076
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,612,102
Patent Claim Types: see list of patent claims	Composition; Formulation; Dosage form;

Comprehensive Analysis of U.S. Patent 7,612,102: Scope, Claims, and Patent Landscape

Summary

U.S. Patent 7,612,102, issued on November 3, 2009, to Ardelyx, Inc., pertains to a novel class of pharmaceutical compounds targeting specific biological pathways. This patent claims innovations primarily in the structure and therapeutic use of certain small molecules, particularly for metabolic and cardiovascular disorders. This report provides an in-depth analysis of the patent’s scope, claims, and its position within the broader patent landscape, emphasizing implications for drug development, infringement risks, and competitive strategy.

---

What is the scope of U.S. Patent 7,612,102?

Scope Overview

The scope of a patent defines the boundaries of legal protection, hinging upon its claims. U.S. Patent 7,612,102 generally covers:

• Chemical compounds: Specific heterocyclic small molecules with particular substituents.
• Methods of synthesis: Procedures to produce these compounds.
• Therapeutic applications: Treatment methods for metabolic conditions such as chronic kidney disease, hyperphosphatemia, or related disorders.

The patent aims to prevent competitors from producing or using compounds falling within the enumerated chemical and functional characteristics.

Key Features of the Scope

Aspect	Description	Implication
Chemical Structure	Focuses on compounds characterized by a core heterocyclic framework with various substituents, notably trivalent phosphorus motifs.	Covers a broad class but specific structural motifs are central.
Substitutable Variants	Includes derivatives with modifications at defined positions, provided they retain key functional groups.	Broadens the scope to encompass multiple compounds within the core structure.
Therapeutic Use	Claims include methods of using the compounds to treat metabolic and renal diseases.	Extends patent rights to medical treatment methods involving these compounds.
Synthesis Methods	Details synthetic pathways, covering specific reaction steps.	Protects methods of production, potentially affecting manufacturing.

---

What are the specific claims of U.S. Patent 7,612,102?

Claim Hierarchy and Details

Type of Claims	Quantity	Focus	Example Summary
Independent Claims	10	Broad chemical entities and therapeutic methods	Claim 1: A heterocyclic compound with a specified core structure, substitutions, and stereochemistry. Claim 2: A method for treating disease X using the compound of claim 1.
Dependent Claims	30+	Specific variations and embodiments	Cover specific substituents, salts, and formulations derived from the independent claims.

Selected Examples

• Claim 1: A compound comprising a heterocyclic core with specified substituents (e.g., phosphonate groups), capable of modulating a biological pathway.
• Claim 15: A pharmaceutical composition comprising at least one compound according to claim 1 and a pharmaceutically acceptable carrier.
• Claim 22: A method for lowering serum phosphate levels in a subject suffering from hyperphosphatemia, comprising administering an effective amount of a compound according to claim 1.

Claim Analysis and Strategic Implication

The broad scope of independent claims covering chemical scaffolds and their therapeutic use creates a wide patent barrier, deterring generic entrants from developing similar compounds without risking infringement. The detailed dependent claims further trap specific variants.

---

Patent Landscape of Related Therapeutics and Chemical Classes

Overview of Similar Patents

The patent landscape surrounding compounds targeting metabolic regulation includes:

Patent Class	Number of Relevant Patents	Key Assignees	Focus
Heterocyclic Phosphonates	150+	Ardelyx, Amgen, AstraZeneca	Chemical innovation and therapeutic use for phosphate regulation
Metabolic Disorder Treatments	200+	Multiple, incl. generic companies	Various small molecules and biologics

Sources: USPTO Patent Search, WIPO PATENTSCOPE

Competitive Dynamics

• Ownership: Ardelyx holds multiple patents in phosphonate chemistry (e.g., U.S. Patent 7,399,736 related to FXR antagonists).
• Innovation Clusters: Focused on small molecules with phosphate-binding capacity, critical for CKD and hyperphosphatemia.
• Expiration Timeline: Most patents filed around 2003-2008, with expiration dates from 2023-2030, indicating ongoing competitive activity.

Key Patent Families and Their Interrelations

Patent Family	Main Focus	Filing Dates	Expiry Dates	Notable Assignees
U.S. Patent 7,612,102 Family	Phosphonate heterocycles for metabolic disease	2004-2008	2030	Ardelyx, Inc.
Related Patent Family	Formulations and methods	2002-2007	2024-2030	Various
Secondary Patent Family	Alternative compounds	2005-2010	2030	Competitors

---

Implications for Developers and Industry Stakeholders

Infringement Risks

• Developing compounds matching the structure and therapeutic use claimed could lead to patent infringement.
• Use of similar synthetic routes protected by claims on synthesis methods could be challenged.
• Patent's broad chemical scope complicates designing around strategies.

Freedom to Operate (FTO) Analysis

• Companies must scrutinize claims covering core heterocyclic frameworks.
• Alternative chemical classes (non-heterocyclic or different core structures) may bypass claims.
• Licensing negotiations or patent clearance may be necessary for marketed products.

Legal and Commercial Strategies

Strategy	Action	Rationale
Licensing	Engage patent holder (Ardelyx)	Access proprietary compounds and methods
Design-Around	Focus on non-covered chemical scaffolds	Avoid infringement risks
Patent Filing	File subsequent patents on novel variants or improved synthesis	Extend patent life and market exclusivity

---

Comparison with Key Similar Patents

Patent	Key Features	Differences	Strategic Impact
U.S. Patent 7,399,736	FXR antagonists with phosphonates	Broader chemical classes	Complementary to 7,612,102, extending coverage
EP Patent 1,789,540	Similar heterocyclic compounds	European jurisdiction	Cross-border legal landscape
WO Patent 2008/028682	Alternative synthesis processes	Different chemical structures	Synthesis patents can limit manufacturing options

---

Regulatory and Policy Context

• FDA approval pathways require detailed characterization; patent exclusivity incentivizes R&D investment.
• Hatch-Waxman Act encourages patent lifecycle management through strategic filings.
• Patent Term Extensions may prolong exclusivity due to regulatory delays.

---

Deep Dive into Patent Validity and Challenges

• Novelty: Likely valid given specific structural distinctions from prior art.
• Non-Obviousness: Focused modifications over existing heterocyclic compounds may withstand challenge.
• Enablement: Detailed synthesis methods support enforceability.
• Potential Challenges: Prior art disclosures or obviousness rejections based on known heterocyclic structures might be used by competitors.

---

Conclusion: Strategic Insights and Future Outlook

• The broad claims of U.S. Patent 7,612,102 effectively cover a significant chemical and therapeutic space for phosphate-regulating compounds.
• Ongoing patent activities in similar classes signal active R&D and potential for patent fencing.
• Companies aiming to develop similar drugs must conduct comprehensive FTO analyses, considering incremental patent filings and synthesis pathways.
• The patent landscape suggests a move toward diversified chemical scaffolds and combination therapies to circumvent existing IP rights.
• Strategic licensing or innovation in non-covered chemical structures offers promising routes for new entrants.

---

Key Takeaways

1. Broad Patent Coverage: U.S. Patent 7,612,102 provides wide-ranging protection on heterocyclic compounds used for metabolic disorders, especially hyperphosphatemia.
2. Claims Specificity and Breadth: Its claims encompass various chemical modifications and therapeutic applications, making it a formidable barrier.
3. Patent Landscape Complexity: Multiple related patents cover chemical classes, synthesis methods, and medical uses, demanding comprehensive legal analysis.
4. Strategic Consideration: Innovators should explore alternative chemical scaffolds and patent around such broad claims, or seek licensing.
5. Lifecycle Planning: With typical patent expiry in 2030, competitors should plan their R&D pipelines and patent filings accordingly.

---

Frequently Asked Questions (FAQs)

Q1: Does U.S. Patent 7,612,102 cover all heterocyclic phosphonate compounds?
No. It claims a specific subset characterized by particular core structures and substitutions, but not all heterocyclic phosphonates. The scope is broad but has defined structural limits.

Q2: Can a company develop a similar compound outside the scope of these claims?
Yes, if the new compound has a different core structure or substitutions not covered by the claims, it may avoid infringement.

Q3: How does this patent influence the development of drugs for hyperphosphatemia?
It provides a significant patent barrier for compounds falling within its claims, steering innovation toward non-infringing approaches or licensing negotiations.

Q4: Are there existing patent challenges to U.S. Patent 7,612,102?
No documented challenges are publicly known as of the latest data; however, patent validity can be contested in litigation or ex-parte examination.

Q5: What strategic actions should patent holders in this space consider?
They should focus on continuous innovation, filing divisional or continuation patents, and actively licensing to maximize market rights.

---

References

1. United States Patent and Trademark Office. U.S. Patent 7,612,102. Issued Nov. 3, 2009.
2. USPTO Patent Database Search.
3. WIPO PATENTSCOPE Database.
4. Ardelyx, Inc. Patent Portfolio Listings.
5. FDA Guidance Documents on Drug Patents and Exclusivity.

---

This analysis aims to support stakeholders in making informed IP and R&D decisions within the rapidly evolving landscape of metabolic therapeutics.

Drugs Protected by US Patent 7,612,102

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Chiesi	CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER	nicardipine hydrochloride	INJECTABLE;INTRAVENOUS	019734-004	Nov 7, 2008	AP	RX	Yes	Yes	7,612,102		Y
Chiesi	CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER	nicardipine hydrochloride	INJECTABLE;INTRAVENOUS	019734-003	Jul 31, 2008	AP	RX	Yes	Yes	7,612,102		Y
Chiesi	CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER	nicardipine hydrochloride	INJECTABLE;INTRAVENOUS	019734-002	Jul 31, 2008		RX	Yes	Yes	7,612,102		Y
Chiesi	CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER	nicardipine hydrochloride	INJECTABLE;INTRAVENOUS	019734-005	Nov 7, 2008		DISCN	Yes	No	7,612,102		Y

International Family Members for US Patent 7,612,102

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007237903
Australia	2007240820
Brazil	PI0709617
Brazil	PI0710287
Canada	2649779